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FenoﬁbrateObesity is associated with an increased risk for malignant lymphoma development. We used Bcr/Abl
transformed B cells to determine the impact of aggressive lymphoma formation on systemic lipid mobilization
and turnover. In wild-type mice, tumor size signiﬁcantly correlated with depletion of white adipose tissues
(WAT), resulting in increased serum free fatty acid (FFA) concentrations which promote B-cell proliferation in
vitro. Moreover, B-cell tumor development induced hepatic lipid accumulation due to enhanced hepatic fatty
acid (FA) uptake and impaired FA oxidation. Serum triglyceride, FFA, phospholipid and cholesterol levels were
signiﬁcantly elevated. Consistently, serum VLDL/LDL-cholesterol and apolipoprotein B levels were drastically
increased. These ﬁndings suggest that B-cell tumors trigger systemic lipid mobilization from WAT to the liver
and increase VLDL/LDL release from the liver to promote tumor growth. Further support for this concept
stems from experiments where we used the peroxisome proliferator-activated receptor α (PPARα) agonist
and lipid-lowering drug fenoﬁbrate that signiﬁcantly suppressed tumor growth independent of angiogenesis
and inﬂammation. In addition to WAT depletion, fenoﬁbrate further stimulated FFA uptake by the liver and re-
stored hepatic FA oxidation capacity, thereby accelerating the clearance of lipids released from WAT. Further-
more, fenoﬁbrate blocked hepatic lipid release induced by the tumors. In contrast, lipid utilization in the
tumor tissue itself was not increased by fenoﬁbrate which correlates with extremely low expression levels of
PPARα in B-cells. Our data show that fenoﬁbrate associated effects on hepatic lipid metabolism and deprivation
of serum lipids are capable to suppress B-cell lymphoma growth which may direct novel treatment strategies.
This article is part of a Special Issue entitled Lipid Metabolism in Cancer.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Obesity is one of the most common public health problems world-
wide as it is associated with metabolic syndrome, hepatosteatosis, ath-
erosclerosis, diabetes, and other metabolic diseases. Recent evidence
also ﬁrmly linked obesity to an increased risk for developing several
malignant tumors. Calle et al. reported that a body mass index (BMI)Metabolism in Cancer.
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B.V. Open access under CC BY-NC-NDof >40 is signiﬁcantly related to higher rates of death due to cancer of
the esophagus, colon and rectum, liver, gallbladder, pancreas, and
kidney, as well as multiple myeloma and malignant lymphoma [1].
Malignant lymphoma presents a diverse group of malignancies of the
lymphatic system with diffuse large B-cell lymphoma being the most
common aggressive form. A meta-analysis of prospective studies re-
garding the association of BMI with the incidence andmortality for ma-
lignant lymphoma revealed that BMI is positively associated with an
increased risk for developing diffuse large B-cell andHodgkin's lympho-
ma [2]. Elevated hormone levels including adipokines (e.g. leptin [3])
and growth factors (e.g. insulin-like growth factor [4,5]) might partially
explain the underlying mechanism. However, a potential direct impact
of excess lipid supply on B-cell lymphoma growth and progression
remains unclear. Several groups reported decreased serum levels of
total cholesterol (TC) and increased triglyceride (TG) concentrations
in patients with solid tumors [6–8]. Similar results were observed in license.
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for different types of malignant lymphoma such as diffuse large B-cell
lymphoma and Burkitt's lymphoma, which are characterized by one of
the fastest growth rates of human malignancies.
Peroxisome proliferator-activated receptor alpha (PPARα) belongs
to the nuclear receptor family, which modulates gene transcription in
response to speciﬁc endogenous and exogenous ligands such as fatty
acids (FA) [10] and ﬁbrates [11], respectively. PPARαwas originally de-
scribed as a central regulator of lipid metabolism but also plays a key
role in modulating the inﬂammatory response in various tissues
(reviewed in [12]). Its agonists are widely used to treat hyperlipidemic
disorders [10]. Recently, tumor suppression mediated by PPARα ago-
nists in various types of tumors (reviewed in [13]) has supported
their beneﬁcial “off target” effects against aggressive tumors. Themech-
anisms and potential connection of the lipid-lowering properties of
PPARα agonists to tumor suppression are still poorly understood.
Our study aims to analyze the systemic effects of B-cell tumors
on lipid metabolism and to evaluate the lipid-lowering effect of PPARα
agonists on B-cell tumor growth using a mouse model. B-cell tumor
caused loss of white adipose tissue (WAT) resulting in increased
serum FA, TG, phospholipids (PL), TC and free cholesterol levels. Hepatic
lipid metabolismwas profoundly altered and export of lipids from liver
increased. Treatment with the PPARα agonist fenoﬁbrate decreased
serum lipid parameters as well as TG- and cholesterol-rich lipoproteins.
Tumor growth was dramatically suppressed by fenoﬁbrate. These re-
sults indicate that the use of lipid-lowering drugs might be a novel po-
tential approach to treat fast-growing B-cell lymphoma like diffuse
large B-cell lymphoma.
2. Materials and methods
2.1. Animal housing
Ten to twelve week old male C57Bl/6J and PPARα knock-out mice
were housed under a 12 h light/dark cycle and permitted ad libitum
consumption of water and food. During experiments, food intake and
body weight were monitored. All experimental protocols were per-
formed in accordance with animal protocol BMWF-66.010/0110-II/3b/
2010, as approved by the Austrian government.
2.2. Creation and maintenance of Bcr/Abl-transformed B-cells
Bcr/Abl-transformed B-cellswere created as previously reported [14].
Brieﬂy, bone marrow was isolated from C57Bl/6J mice. Cells were trans-
ducedusingGFP/p185bcr/abl viral supernatant fromΦ-NX (Phoenix) cells.
GFP is used as a transduction marker for primary positive cell selection.
Candidate cell lineages were further sorted by ﬂuorescence-activated
cell sorting (FACS) based on expression of the B-cell markers B220,
CD43 and CD19. Stable Bcr/Abl-transduced B-cells were selected by pu-
romycin and maintained in RPMI 1640 medium containing 10% FBS
(PAA, Pasching, Austria) in a 37 °C incubator with 5% CO2.
2.3. Lipid supplementation and Wy14643 stimulation
For lipid supplementation experiments, 5 × 105 Bcr/Abl-transduced
B-cells were seeded in 9.5 cm2 wells and incubated in 2 mL serum-free
mediumsupplementedwith puriﬁedhumanVLDL (Chemicon,Millipore,
USA) or Chemically Deﬁned Lipid Concentrate® containing cholesterol
(220 mg/L), arachidonic acid (2 mg/L), linoleic acid, linolenic acid,
myristic acid, oleic acid, palmitic acid, palmitoleic acid and stearic acid
(10 mg/L each) (Invitrogen, Vienna, Austria). After 24 h, cells were
counted in a CASY cell counter (Schärfe System GmbH, Germany). For
Wy14643 (Cayman Chemical, Michigan, USA) stimulation, cells were
seeded as mentioned above, treated with 50 μM Wy14643, and har-
vested after 24 h (for RNA extraction) or analyzed after 24, 48, 72 h, re-
spectively, to determine growth characteristics.2.4. Tumor implantation, feeding and tissue harvesting
Animals were divided into four groups as indicated. 1.5 × 105 Bcr/
Abl-transformed B-cells, obtained from an exponentially proliferating
cell culture, or saline solution as negative control were injected sub-
cutaneously at dorsum below the neck. Mice were fed with regular
chow diet (4.5% w/w fat) or chow diet mixed with 0.2% w/w
fenoﬁbrate (Sigma-Aldrich, Germany). After 13 to 15 days (for tumor-
WAT correlation) or 13 days (fenoﬁbrate treatment), mice were anes-
thetized using isoﬂurane and blood was isolated by retro-orbital punc-
ture. Thereafter, mice were sacriﬁced by cervical dislocation and tissues
were rapidly excised, weighed, and either frozen in liquid nitrogen or
stored in 4% neutral-buffered formalin for subsequent preparation of
parafﬁn blocks.
2.5. Serum lipid and lipoprotein analysis
Blood was collected as described above and centrifuged for 20 min
at 1800g. Serum was stored at −80 °C until analysis. Serum TG, total
and free cholesterol, PL (DiaSys, Germany), and free fatty acids (FFA)
(Wako, Germany) were quantiﬁed spectrophotometrically. Serum lipo-
proteins were separated by lipid electrophoresis and visualized using
the SAS-3 Cholesterol Proﬁle Kit according to the manufacturer's in-
struction (Helena BioSciences Europe, Sunderland, UK). The lipoprotein
fractions of each electrophoretic pattern were quantiﬁed by densitom-
etry and evaluated according to the integrated densitometric peak
areas [15]. In the human sample, the α band with the fastest migration
corresponds to HDL while the slowest β band indicates LDLs and pre-β
in between corresponds to VLDL. 200 μL plasma pools from each condi-
tion were subjected to fast protein liquid chromatography (FPLC)
(Pharmacia P-500; Pﬁzer Pharma, Karlsruhe, Germany) equipped with
a Superose 6 column (Amersham Biosciences, Piscataway, NJ). Lipopro-
teins were eluted with 10 mM Tris–HCl, 1 mM EDTA, 0.9% NaCl, and
0.02% NaN3 (pH 7.4). Total cholesterol (TC) and triglyceride (TG) con-
centrations in 0.5 mL fractions were measured enzymatically (TC:
Greiner Diagnostics AG, Bahlingen, Germany; TG: DiaSys, Holzheim,
Germany). To enhance sensitivity, sodium 3,5-dichloro-2-hydroxy-
benzenesulfonate was added to the reaction buffer. Quantitative immu-
noturbidimetric assays for apolipoprotein (Apo) B, ApoCII, and ApoCIII
were obtained from Rolf Greiner Biochemica (Flacht, Germany). Assays
were performed on a Hitachi 917 automated analyzer (Boehringer
Mannheim, Germany).
2.6. Quantitative reverse transcription real-time PCR
Real time PCR was performed as described previously [16]. Total
RNA was extracted from liver, dissected tumor tissue or cultured
cells using Trizol LS (Invitrogen, Vienna, Austria). cDNA was synthe-
sized with High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Vienna, Austria). For qPCR, SYBR Green PCR Master Mix
from Invitrogen and the Applied Biosystems 7900 HT Sequence Detec-
tion Systemwere used. Primers sequences are available upon request.
2.7. Hepatic TG and FFA determination
Liver samples were washed with phosphate-buffered saline (PBS),
weighed and frozen. Total lipids were extracted by the method of
Folch [17]. Lipids were dried and reconstituted by brief sonication in
0.1% Triton-X 100. TG and FFA contents were quantiﬁed as described
above. For histology, two μm thick frozen liver sections were cut and
stained with hematoxylin and eosin (H&E) and Oil Red O staining.
2.8. Tissue FA uptake
Liver and tumor tissueswere excised,weighed, and30–50 mgpieces
were used for the assay. Tissues were washed with PBS containing
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size pieces and washed with PBS containing 5 mM EDTA. The substrate
containing 2.5 mM oleate:BSA complex and 2 μCi/mL [14C] oleate as ra-
dioactive tracer was incubated with the samples in a 24-well plate for
1 h at 37 °C under regular shaking. [14C] oleate uptake and remaining
radioactivity in the medium were determined by liquid scintillation
counting. The amount of absorbed FA was calculated by determining
(initial–ﬁnal radioactivity in themedia) and normalized by protein con-
tent as determined by the DC™ Protein Assay (Bio-Rad, Austria) accord-
ing to the manufacturer protocol.
2.9. Histology and immunohistochemistry
Tumors of sacriﬁcedmicewere carefully isolated, ﬁxed in 4% neutral
buffered formaldehyde solution for 24 h and embedded in parafﬁn
while livers were frozen in liquid nitrogen. 2 μm thick sections were
cut and stained with hematoxylin and eosin (H&E). Caspase-3, CD31,
Ki67 and F4/80 IHC were performed using speciﬁc antibodies against
active caspase-3 (R&D, USA), CD31 (Thermo scientiﬁc, USA), Ki67
(Novocastra, UK) and F4/80 (Serotec, USA) respectively and appropri-
ate secondary antibodies as previously described [16]. For determina-
tion of vessel density, the slides were scanned and CD31-positive cells
were quantiﬁed and normalized to total analyzed area using ScanScope
software (Aperio technologies, USA). For quantiﬁcation of caspase-3
positive cells, the slides were scanned at 40×magniﬁcation and manu-
ally quantiﬁed in 60 power ﬁelds.
2.10. ELISA
TNFα and IL-6 quantitative ELISA kits were purchased from
eBioscience (Vienna, Austria). For serum samples, diluted serum (1:2)
was loaded. For tumor lysates, 40–60 mg frozen samples were homog-
enized byMagNa Lyzer (Roche, Germany) for 3 × 15 s at 6500g in RIPA
lysis buffer with proteinase inhibitor cocktail (Pierce, Germany), then
kept on ice for 20 min. After centrifugation for 10 min at 4000g, protein
concentrations in lysates were determined as described above. 50 μg
proteins were loaded in each 96-well plate. ELISA was performed
according to the manufacturer protocol.
2.11. Statistics
Data are presented as mean ± SEM. Statistical analysis was per-
formed using GraphPad Prism 5. Statistical signiﬁcancewas determined
by the Student's unpaired two-tailed t test. Correlation was studied by
Pearson's correlation test. Group differences were considered signiﬁ-
cant for P b 0.05 (*, #, §), P b 0.01 (**, ##, §§), P b 0.001 (***, ###, §§§).
3. Results
3.1. Inﬂuence of PPARα agonists on B-cell proliferation in vivo
and in vitro
We conﬁrmed the high proliferation rate of Bcr/Abl B-cells in vivo
using subcutaneous implantation with low cell number and under
short term conditions as well as in vitro by counting cell doubling time
(data not shown). Fenoﬁbrate is a serum lipid lowering drug that acts
by stimulating PPARα activation [11] and possesses anti-tumorigenic
properties against several tumor types [13]. In line with this report 0.2%
fenoﬁbrate treatment for 13 days signiﬁcantly suppressed Bcr/Abl trans-
duced B-cell tumor proliferation in vivo in wild-type mice (−68.1%,
P b 0.001) but not in PPARα knock-out mice (−16.1%, P = 0.681)
(Fig. 1A). Interestingly, although B-cell tumors in PPARα knock-out
mice were not sensitive to fenoﬁbrate, tumors in PPARα knock-out
mice were smaller than in wild typemice (−57.3%, P = 0.03). To deter-
minewhether PPARα activation directly inhibits tumor cell proliferation,we investigated the impact of a PPARα agonist on B-cell proliferation in
vitro. As fenoﬁbrate (a methylethyl ester of fenoﬁbric acid) requires
de-esteriﬁcation via a hepatic esterase to its phamacologically active
form—fenoﬁbric acid [18,19], we used the PPARα agonist Wy14643
which does not need activation and shares similar properties with
fenoﬁbrate regarding lipid metabolism and tumor suppression for in
vitro experiments. Surprisingly, Wy14643 failed to alter growth of Bcr/
Abl transformed B-cells in vitro (Fig. 1B). The tumor suppressive effects
of PPARα agonists have been attributed to the inhibition of angiogenesis.
In contrast to previous ﬁndings in B16-F10 melanoma models [20], no
signiﬁcant differences regarding tumor vessel density were found in
lymphomas treated with fenoﬁbrate (Fig. 1C, D). In agreement with
this ﬁnding, vascular endothelial growth factor A (VEGF-A) protein ex-
pression in tumor lysates was not affected by fenoﬁbrate treatment
(Fig. 1E). Despite the lack of effects on protein expression, vascular endo-
thelial growth factor A (VEGF-A)mRNAwas signiﬁcantly downregulated
in tumor tissue after fenoﬁbrate treatment (Fig. 1F). Interestingly, no
change of VEGF-A expression was detected in vitro afterWy14643 treat-
ment (Fig. 1F).
Pro-apoptotic property of fenoﬁbrate was reported in mantle cell
lymphoma in vitro [21]. However, in our tumor model, apoptotic
cells were only rarely observed in fenoﬁbrate treated as well as
untreated tumors (Fig. S1B). Albeit we did ﬁnd a small but not signif-
icant increase of apoptotic cells upon fenoﬁbrate treatment (Fig. S1C),
the low total number of apoptotic cells in tumors rules out that these
differences account for the observed reduction in tumor growth.
Anti-inﬂammatory properties of fenoﬁbrate have been reported
[12,22] and may modulate the interaction of the B-cell tumor with
PPARα positive inﬂammatory cells in the tumor microenvironment.
Several inﬂammatorymediators (e.g. IL-6) are integral to Bcr/Abl driven
tumorigenesis [23,24] and associated with poor outcome of B-cell lym-
phoma [25]. We therefore determined TNFα and IL-6 concentrations in
serum and tumor lysates. Both were undetectable in the control group
while highly expressed in tumor bearing mice (Fig. 1G). Remarkably,
fenoﬁbrate treatment did not reduce their level in tumor bearing mice
(Fig. 1G, H). This might be related to the low level of tumor inﬁltrating
macrophages (Fig. S1D).3.2. B-cell tumors and fenoﬁbrate treatment induce loss of WAT while
fenoﬁbrate reverses tumor-induced increased serum FFA levels
As Bcr/Abl-transformed B-cell tumors grow very rapidly in vivo and
in vitrowe speculated that there might be an increased demand for nu-
trients such as FFA that in vivomight be supplied by systemic lipid mo-
bilization. Indeed, loss ofWATwas observed in tumor bearingwild type
mice and a clear inverse correlation between tumor weight and WAT
weight was observed (R2 = 0.43, P b 0.01) (Fig. 2A). To account for
the potential effect of very large tumor size on metabolic regulation
and energy expenditure we monitored food intake (Fig. S3) and
checked the physiological state of the animals from the time tumors be-
came palpable until the end of the experiment. Food intake did not dif-
fer signiﬁcantly among experimental groups and was not correlated to
tumor size (non-tumor group average 4.22 g, b4 g tumor group
4.07 g, >4 g tumor group 3.82 g per day).We also did not detect abnor-
mal behavior or overt signs of discomfort or sickness. WAT loss differed
amongWAT types. A signiﬁcant loss of 40.3% and 25.3% was detected in
visceral and gonadal WAT, respectively, while it was not signiﬁcant in
perirenal WAT (−38.2%, P = 0.13) compared to control (Fig. 2B–D).
These data indicate an association between tumor growth and lipolysis.
Consistent with this ﬁnding, an increase of serum FFA levels (52.8%,
P b 0.004) was observed in tumor bearing mice compared to healthy
controls (Fig. 2E). It is conceivable that the released FFA might directly
support B-cell growth. To address this, we subjected Bcr/Abl trans-
formed B-cells in vitro to media containing deﬁned lipid mixture
consisting of multiple types of FA and cholesterol or puriﬁed human
1558 J. Huang et al. / Biochimica et Biophysica Acta 1831 (2013) 1555–1565VLDL. Indeed, both the lipid mixture as well as puriﬁed VLDL increased
B-cell proliferation in vitro signiﬁcantly by 53.6% and 42.6%, respectively
(Fig. 2F, G).We further speculated that fenoﬁbrate treatment might be able to
reverse tumor associated changes in lipid metabolism. In agreement
with previous reports in normal (non-tumor) mice [26], fenoﬁbrate
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and by 65.4% in tumor bearing animals after 13 days (Fig. 2B). Indeed,
fenoﬁbrate reversed the tumor-induced increase of serum FA and
lowered it by 31.6%, (P b 0.001) while there was no signiﬁcant FFA
lowering effect in non-tumor bearing control mice (Fig. 2E).
3.3. Impact of fenoﬁbrate on tumor induced impairment of hepatic
lipid metabolism
As the liver is the main organ for uptake of FFA released fromWAT
and subsequent esteriﬁcation into TG for storage or export into the
circulation [27], hepatic lipid turnover might be an important factor
modulating the cachexia-associated effects conferred by B-cell tumor
growth. In spite of WAT loss, total body weight increased in tumor-
bearing mice mainly due to increased liver and spleen mass and severe
skin edema (Fig. 3A, B and Fig. S2), whereas food intake did not differ
signiﬁcantly (Fig. S3). Fenoﬁbrate treatment reduced body weight
while increasing liver mass both in tumor-bearing (Tu) and non-
tumor bearing control mice (Fig. 3A, B). As expected, fenoﬁbrate treat-
ment was accompanied by an increased percentage of Ki67 positive
cells as determined by immunohistochemistry (data not shown). The
reduction in body weight in tumor bearing fenoﬁbrate treated mice is
likely due to the lack of skin edema. Strikingly, liver mass was also in-
creased by 50.1%, (P b 0.001) in tumor-bearing mice receiving regular
chow (Fig. 3B). In addition to increased lipid storage, proliferation of
hepatocytes as shown by an increased mitotic rate (Fig. S4) and by an
increased percentage of Ki67 positive cells determined by immunohis-
tochemistry (data not shown) might substantially contribute to the
observed increased liver mass. Relative hepatic TG content was not
signiﬁcantly altered in tumor-bearing mice fed with regular chow,
whereas fenoﬁbrate treatment increased TG storage in non-tumor and
tumor-bearing mice by 61.4% and 91.2%, respectively, compared with
non-tumor bearing mice fed with regular chow (Fig. 3C). Increased
total liver TG content was found in tumor-bearingmice fedwith regular
chow (75.8%, P = 0.008) with additional increments of liver TG content
in the two fenoﬁbrate-treated groups (188.2%, P = 0.002 for non-tumor
bearing and 288.7%, P = 0.008 for tumor-bearing mice) (Fig. 3D). Con-
sistently, oleate uptakewas enhanced by 42.2% in the liver of non-tumor
bearing fenoﬁbrate treatedmice, by 97.3% in tumor bearingmice fed reg-
ular chow and by 166.6% in tumor bearing fenoﬁbrate treated mice
(Fig. 3E). However, only non-tumor bearing fenoﬁbrate treated mice
showed a signiﬁcantly increased FFA content (21.4%, P = 0.05). This
might be attributed to accelerated FA esteriﬁcation in tumor bearing
mice.
PPARα-mediatedhepatic FA oxidation plays a critical role in clearing
intracellular lipids from the liver [28]. Notably, mRNA expression levels
of PPARα and its target genes PGC1α, CPT1α, ACOX1 and MCAD were
down-regulated in tumor-bearing mice compared with control mice
fed with regular chow. In fenoﬁbrate-treated mice, reduced mRNA
levels of the PPARα target genes CPT1α, ACOX1 and MCAD in tumor-
bearing mice were restored to or even beyond normal levels but did
not reach the same level as in non-tumor bearing fenoﬁbrate-treated
mice [Fig. 3G]. These results suggest that FA β-oxidation is impaired
by tumor growth.
3.4. Impact of fenoﬁbrate on tumor-induced hepatic lipid release
The liver is the main organ for TG and cholesterol synthesis, which
are released as lipoproteins into the circulation [27]. Serum levels of
TG, total cholesterol, free cholesterol and PL were increased inFig. 1. Fenoﬁbrate suppresses B-cell tumor growth independent of angiogenesis and inﬂammatio
(ko)mice (n = 4–5 per group) fedwith regular chowor chow supplementedwith 0.2% (w/w) fe
Abl-transformed B-cells. (B) The effect ofWy14643 (50 μM)onB-cell proliferation in 10% FBSme
CD31 on sections of parafﬁn-embedded tumor specimen fromwtmice. (D) Number of CD31 pos
by ELISA. (F) VEGF-AmRNA expression in vivo and in vitro after PPARα stimulation (fenoﬁbrate in
lysates were determined by ELISA (n = 7). Data are presented as mean ± SEM. *, P b 0.05; ***,tumor-bearing mice compared with non-tumor bearing control
mice (by 92.6%, 54.7%, 152.6%, and 36.5%, respectively) (Fig. 4A–D).
Interestingly, fenoﬁbrate treatment completely reversed this increase
(−51.4%, 11%, 25.1% and −4.9%, respectively, compared with
non-tumor bearing control mice) and lowered lipid levels to those
of non-tumor bearing fenoﬁbrate-treated mice (Fig. 4A–D).
To determine which lipoprotein(s) is/are responsible for the ob-
served increase of serum lipids in B-cell tumor-bearing mice, we
performed lipid electrophoresis. We found the band with lowest mobil-
ity to be drastically increased compared to other lipoproteins detectable
in tumor-bearing mice (Fig. 4E). Fenoﬁbrate treatment reduced this
band to normal levels in tumor-bearing mice. In humans, HDL, VLDL,
and LDL are termed α, pre-β, and β bands, respectively, based on their
characteristic surface charges [15]. We therefore speculate that the
lower band in tumor-bearing mice is a fused band of pre-β and β
lipoproteins equivalent to VLDL and LDL. Further FLPC analysis con-
ﬁrmed the profound increase in VLDL accompanied by LDL in tumor
bearing mice fed with regular chow compared to control mice (Fig. 4F).
Fenoﬁbrate reduced VLDL level in non-tumor bearingmice and depleted
VLDL and LDL dramatically in tumor bearing mice (Fig. 4F). Increased
cholesterol in tumor-bearing mice corresponds to VLDL/LDL-cholesterol
(281.1%, Fig. 4G) but not to HDL-cholesterol (Fig. S5). In agreement with
these observations, the serum concentration of ApoB, which is found in
lipoproteins originating from liver (VLDL, IDL, LDL) or intestine (chylo-
micron) and is well established as a predictor of VLDL/LDL levels, was in-
creased by 3-fold in tumor-bearing mice (Fig. 4H). As expected,
fenoﬁbrate remarkably reduced serum VLDL/LDL-cholesterol and ApoB
to levels similar as in non-tumor bearing fenoﬁbrate-treated mice
(Fig. 4G, H). ApoCII and CIII are protein components of VLDL; their ratio
(ApoCII/III) reﬂects LPL activity in capillaries. In tumor-bearing mice,
the serum ApoCII/III ratio was slightly increased (18.7%, P = 0.03)
(Fig. 4I) although basal ApoCII and CIII levels were not signiﬁcantly
changed in circulation or in liver (Fig. 4J, K). One might speculate that
more LPL-sensitive VLDL is available in the circulation, thus favoring uti-
lization by the tumor. Similarly, both fenoﬁbrate-treated groups
(non-tumor and tumor-bearing mice) had an increased serum ApoCII/
III ratio (20.6%, P = 0.02 and 30%, P b 0.001, respectively) (Fig. 4H) and
hepatic transcript level of ApoCII increased by 52.4% while ApoCIII de-
ceased by −56.4% in tumor bearing mice fed with fenoﬁbrate (Fig. 4J,
K). Increased ApoCII/III ratio upon fenoﬁbrate might accelerate utiliza-
tion of TG-rich lipoproteins in peripheral organs.
3.5. Response of tumor to WAT loss in fenoﬁbrate-treated mice
As described above, tumor-induced WAT loss resulted in increased
hepatic FA uptake and increased liver mass in fenoﬁbrate-fed mice. In
contrast, the FA uptake by the tumor remained unchanged in
fenoﬁbrate-treated mice (Fig. 5A). In line with this result, intracellular
FFA and TG contents were unaltered (Fig. 5B, C). Similarly, the expres-
sion of genes involved in lipid uptake (VLDLR, LDLR, CD36) and FA syn-
thesis (ACC1, FASN, SREBP1) were unaltered both in vivo and in vitro
(Fig. 5D, E). The fact that PPARαmRNA expression was not detectable
by real time PCR (data not shown) most likely accounts for the lack of
response of B-cell tumors to fenoﬁbrate in vivo or to Wy14643 in vitro.
This assumption is further supported by the fact that the PPARα targets
(CD36, MCAD, and ACOX1) generally showed no signiﬁcant responses
to PPARα agonist in vivo and in vitro (Fig. 5D, E). These data and the
fact that tumor growth was unaltered by fenoﬁbrate treatment in
PPARα knockout mice (Fig. 1B) strongly suggest that fenoﬁbrate sup-
presses B-cells' tumor growth independent of PPARα activation in then. (A) Tumorweights inwild type (wt)mice (n = 13 for each group) and PPARα knock-out
noﬁbratewere determined on day 13 aftermice had been injected subcutaneouslywith Bcr/
diawas assessed by counting the cell number (n = 3). (C) Immunohistochemical staining of
itive cells/mm2 tumor area (n = 5). (E) VEGF-A protein content in tumor lysates quantiﬁed
vivo andWY14643 in vitro, respectively) (n = 4). TNFα and IL-6 in (G) serumor (H) tumor
P b 0.001.
Fig. 2. B-cell tumors induceWAT loss and elevation of serum FFA. (A) Inverse correlation between tumorweight and gonadalWATweight (n = 17) determined 13–15 days after tumor
cell injection. Signiﬁcancewas studied by Pearson's correlation test. (B) Gonadal, (C) perirenal and (D) visceralWATweights and (E) serum FFA concentration ofmice (Tu: tumor-bearing;
Non-Tu: non-tumor control), fed with regular chow (R.C.) or fenoﬁbrate-supplemented chow (Feno) after 13 days of treatment. (F, G) In vitro cell proliferation after lipid supplement.
(F) Chemically Deﬁned Lipid Concentrate® (Gibco®) or (G) puriﬁed human VLDL was added into serum-free RPMI media and the cell number was determined after 24 h. Data are
presented as mean ± SEM (n = 3–5). *, P b 0.05; **, P b 0.01;***, P b 0.001 denote signiﬁcant differences compared to non-tumor bearing mice fed with regular chow (Non-Tu R.C.)
while # or § denote signiﬁcant differences compared to tumor-injected mice fed with regular chow (Tu R.C.) or non-tumor mice fed with fenoﬁbrate-containing chow (Non-Tu Feno),
respectively.
1560 J. Huang et al. / Biochimica et Biophysica Acta 1831 (2013) 1555–1565B-cell tumor by reversing tumor induced changes in the lipid metabo-
lism of recipient mice.
4. Discussion
The clear link between obesity and increased probability to devel-
op cancer fuels the interest in changes in systemic lipid metabolism
that may promote tumor development and progression. As a conse-
quence lipid lowering drugs may provide novel therapeutic optionsto treat patients suffering from various types of tumors. Most cases
of diffuse large B-cell lymphoma directly arise from regular B cells.
In addition other types of lymphoma such as follicular lymphoma
may transform into diffuse large B-cell lymphoma [29]. In this study
we explored murine Bcr/Abl transformed B-cells [30] as an experi-
mental model for fast-growing B-cell tumors such as diffuse large
B-cell lymphoma and acute lymphoblastic leukemia/lymphoma to
investigate the effects of the growing tumor on systemic lipid mobili-
zation and distribution. The rapidly growing Bcr/Abl transformed
Fig. 3. Tumor growth and fenoﬁbrate feeding increase hepatic lipid content and FA uptake. Fenoﬁbrate increases FA oxidation in liver which is inhibited in tumor bearing mice.
(A) Carcass body weight gain and (B) liver weight were recorded 13 days after tumor cell or saline injection in fenoﬁbrate-treated or control mice. (C) Hepatic TG content was
determined and (D) total liver TG content was calculated as (mg TG/mg liver sample × liver weight (mg)). (E) Ex vivo [14C] oleate uptake and (F) hepatic FFA concentrations
were quantiﬁed (G) Expression proﬁles of PPARα target genes involved in FA oxidation in the liver. Data are presented as mean ± SEM (n = 4–5). Tu: tumor-bearing; Non-Tu:
non-tumor (saline) injected controls, fed with regular chow (R.C.) or fenoﬁbrate-supplemented chow (Feno). * denotes signiﬁcant differences compared with non-tumor injected
mice fed with regular chow (Non-Tu R.C.); # and § denote signiﬁcant differences compared with tumor-injected mice fed with regular chow (Tu R.C.) or non-tumor injected mice
fed with fenoﬁbrate-containing chow (Non-TuFeno) group, respectively.
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tumor-weight. Loss of WAT was accompanied by elevated serum
FFA. FFA directly increased the proliferation of Bcr/Abl B-cells, as
was clearly visible from our experiments using lipid supplement in
vitro. Both a simple lipid formulation (FFA and cholesterol) and com-
plex lipid form (VLDL) increased proliferation of Bcr/Abl B-cells. No
hints for any lipotoxic effects such as an increased rate of apoptosis
were detectable. To sustain the rapid proliferation rate and to match
the high demand of lipids, the lymphoma/leukemia undergoes a
metabolic shift either by increasing lipid anabolism via fatty acid
synthase [31,32] or by withdrawing lipids from the circulation via
LPL [33] or lipoprotein receptors mediated endocytosis. Accelerated
lipid utilization mainly by increased lipid oxidation is a hallmark of
cancer patients affected by tumor associated cachexia [34]. Surpris-
ingly, in our B-cell tumor model, WAT loss was accompanied by a
body weight gain, which is in contrast to our previous ﬁnding in Lewis
lung carcinoma (LLC) or B16 melanoma induced cachexia [35]. A likelyexplanation for this discrepancy might be the combination of a less se-
vere effect on WAT resulting in an incomplete WAT loss, an increased
liver and spleen mass as well as severe skin edema.
The liver is considered the main organ controlling systemic lipid
mobilization; however, effects on liver metabolism in the context of
tumor-associated cachexia are still poorly understood. Here we
show profoundly altered hepatic lipid turnover as well as increased
liver mass as a result of B-cell tumor growth. Increased liver mass in
the fenoﬁbrate treated groups is likely to be caused by an increased
mitotic rate of hepatocytes and by peroxisome proliferation in re-
sponse to PPARα activation while in the untreated tumor bearing
group it might be attributed to hepatocyte proliferation in response
to inﬂammatory mediators (e.g. TNFα, IL-6) released by the lympho-
ma. Remarkably, fenoﬁbrate treatment did not reduce their level in
tumor bearing mice. The low level of tumor inﬁltrating macrophages
as well as the absence of PPARα in Bcr/Abl transformed B cells might
explain the insensitivity of B-cell tumors to fenoﬁbrate stimulation
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Fig. 5. Unaltered tumor lipid metabolism in fenoﬁbrate-treated mice due to absence of PPARα expression in tumor. (A) Oleate uptake, (B) intracellular FFA, and (C) TG concentra-
tions in tumors after fenoﬁbrate treatment. The impact of (D) fenoﬁbrate in vivo and (E) Wy14643 in vitro on the expression of genes involved in lipid metabolism. Data are
presented as mean ± SEM (n = 3–5). *, P b 0.05; **, P b 0.01.
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fenoﬁbrate might block other pro-inﬂammatory stimuli thereby in-
ﬂuencing tumor growth.
In liver, FA are rapidly esteriﬁed into TG, which are either stored
within lipid droplets or exported as VLDL. In line with another tumor
model [36], hepatic FA oxidation was suppressed in tumor-bearing an-
imals. Notably, genes encoding for FA uptake and de novo lipogenesis
did not change signiﬁcantly (data not shown). Strikingly, serum lipid
parameters were remarkably elevated in tumor-bearing mice. Our
data strongly indicate that TG and synthesized cholesterol in the liver
are transported into the circulation initially by VLDL and secondarilyFig. 4. Fenoﬁbrate suppresses tumor-induced hepatic lipid export. (A–D) Serum triglyceride
mined. (E) VLDL, LDL, and HDL in serum were separated by lipid electrophoresis. Human ser
band indicates LDL, pre-β corresponds to VLDL. Lipoproteins were visualized by enzymatic
Platinum Software according to the integrated densitometric peak areas and their (G) chole
tration”. (F) Lipoprotein analyses by FPLC. Distribution of TC and TG in pooled plasma fro
FPLC separation were determined spectrophotometrically. (H) ApoB, (I) ApoCII, and ApoCIII
manually. The transcript levels of (J) ApoCII and (K) ApoCIII were also checked by qPCR. Dat
with non-tumor injected mice fed with regular chow (Non-Tu R.C.); # denotes signiﬁcant dby LDL. The increased removal of lipids from the livermight be compen-
sated by increased hepatic FA uptake and decreased FA oxidation in
tumor-bearing mice.
Elevated plasma levels of TG are a hallmark of the metabolic syn-
drome and a risk factor for atherosclerosis [37]. In addition, VLDL-C/
LDL-C are considered as “bad cholesterol” by distributing cholesterol
to peripheral organs and hence being associated with the pathogene-
sis of atherosclerosis. Aberrant serum lipid proﬁles might also be
connected to tumor development. Patients suffering from cancer have
signiﬁcantly lower plasma cholesterol, HDL-C, and LDL-C levels and
higher TG concentrations than controls [9]. Similarly, a reduction ofs (TG), total cholesterol (TC), free cholesterol (FC), and phospholipids (PL) were deter-
um (Hu) was used as a positive control: the α band corresponds to HDL whereas the β
staining and VLDL/LDL percentage was determined by densitometry and quantiﬁed by
sterol concentrations were calculated based on the formula “percentage × TC concen-
m mice (n = 4–5) of two independent experiments. TC and TG concentrations after
were determined by immunoturbidimetric assays. The ratio of ApoCII/III was calculated
a are presented as mean ± SEM (n = 4–5). * denotes signiﬁcant differences compared
ifferences compared with tumor-injected mice fed with regular chow (Tu R.C.).
1564 J. Huang et al. / Biochimica et Biophysica Acta 1831 (2013) 1555–1565TC, LDL-C, HDL-C, and BMI was observed in patients with metastatic
compared to patients with non-metastatic solid tumors. However,
serum TG were also decreased in these patients [7], indicating that ad-
vanced cancermight have distinct effects on serum TG. Recent evidence
provided ﬁrst insights into the role of cholesterol for tumor develop-
ment. Experimental models revealed that elevated plasma cholesterol
levels due to dietary effects accelerate the development and aggressive-
ness of breast tumors [38]. Supportively, statins, which have been intro-
duced for the treatment of hypercholesterolemia, display antitumor
effects against various cancers including lymphoma in animal tumor
models [39]. These results argue for an important role of cholesterol in
B-cell lymphoma development and progression, in which elevated
serum cholesterol (mainly VLDL/LDL-C) concentration and LDL levels
were observed.
B-cell tumor-bearing mice developed hyperlipidemia, accompanied
by impaired hepatic FA oxidation. Remarkably, these profoundly altered
metabolic parameters were reversed by fenoﬁbrate treatment, a com-
monly used lipid-lowering agent and PPARα agonist. Fenoﬁbrate re-
versed the elevation of serum lipids in B-cell tumor-bearing mice
presumably by one of the following mechanisms or a combination
thereof: 1) Increased hepatic FA uptake from circulation, which is sup-
ported by studies demonstrating that ﬁbrate promoted hepatic FA up-
take by speciﬁc FATPs [40]. 2) Accelerated FA catabolism as PPARα
plays a pivotal role in promoting FA oxidation in peripheral organs
like liver, heart and muscle [28] but not in B-cell tumors as these lack
PPARα expression. The resulting marked reduction of serum FFA con-
centrations consequently leads to FA starvation of the tumor. 3) Re-
duced cholesterol-rich LDL. Elevated VLDL/LDL-C and LDL levels in
tumor-bearing mice were completely reversed by fenoﬁbrate treat-
ment, indicating that fenoﬁbrate starves the tumor from available
serum cholesterol. 4) Lowering serum TG concentrations via reducing
hepatic TG export as TG-rich VLDL and by enhancing peripheral hydro-
lysis of VLDL. LPL is themain lipase which hydrolyzes TG from VLDL; its
transcriptional level is up-regulated by PPARα agonists via PPAR-
responsive elements in its promoter [41]. PPARα agonist treatment
could also result inmarked depression of hepatic ApoCIII [42,43], a neg-
ative regulator in the clearance of TG-rich VLDL through inhibiting en-
zyme activities of both LPL and hepatic lipase [44]. As a consequence
fenoﬁbrate might deprive tumors of available serum TG by reducing
TG export and/or increasing the capacity of peripheral organs to utilize
TG. The B-cell tumor itself is not affected as it lacks PPARα. Indeed, FA
uptake by the tumor tissue remained unchanged upon fenoﬁbrate
treatment and intracellular FFA and TG contents were unaltered. Inter-
estingly, although B-cell tumors in PPARα knock-out mice were not
sensitive to fenoﬁbrate, tumors in PPARα knock-out mice were smaller
than in wild type mice. This might be due to the high level of
thrombospondin-1 as angiogenesis inhibitor in circulation in PPARα
knock-out mice [45]. Taken together, these data provide evidence that
fenoﬁbrate suppresses B-cells tumor growth via cell extrinsic pathways
and that the tumor suppressing effects are independent of PPARα acti-
vation in the tumor.
To the best of our knowledge our study establishes for the ﬁrst time
that the depletion of WAT in an animal model of B-cell lymphoma is
correlated to tumor size and resulted in profound alterations in lipid
metabolism. These changes include elevated serum FFA, hepatic lipid
accumulation due to increased FA uptake and reduced β-oxidation as
well as drastically altered lipoprotein composition. Tumor growth
could be inhibited by fenoﬁbrate as this drug is capable of interrupting
the systemic changes in lipid metabolism such as hypertriglyceridemia
and hypercholesterolemia in B-cell tumor-bearing mice. In view of the
high sensitivity of B-cell lymphoma to lipid deprivation, the application
of lipid-lowering drugsmay hold great promise as novel and innovative
therapies against B-cell malignancies such as diffuse large B-cell lym-
phoma, Burkitt's lymphoma, and acute B-cell leukemia.
Supplementary data to this article can be found online at http://
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